<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>ECTRIMS</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>MYC inhibition contributes to multiple sclerosis amelioration </title>
      <description>
        <![CDATA[MYC is a transcription factor that plays relevant roles in cellular processes such as glycolysis, development, cell differentiation or proliferation. Recent research has associated the transcriptional activity of MYC to the activation of T cells in multiple sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712976</guid>
      <pubDate>Mon, 30 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712976-myc-inhibition-contributes-to-multiple-sclerosis-amelioration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/WVU-multiple-sclerosis-neuron.webp?t=1667926536" type="image/png" medium="image" fileSize="1909376">
        <media:title type="plain">Multiple sclerosis, neurons concept art.</media:title>
        <media:description type="plain">Artistic representation of multiple sclerosis. Credit: Aira Burkhart, West Virginia University School of Medicine</media:description>
      </media:content>
    </item>
    <item>
      <title>HDAC3 inhibition counteracts autoimmune demyelination in mice</title>
      <description>
        <![CDATA[After a team at the Hospital Universitari Vall d’Hebron found that histone deacetylase 3 (HDAC3) has a role in the chronic inflammatory response in the central nervous system in models of traumatic brain injury, they investigated its role in autoimmune demyelination.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712973</guid>
      <pubDate>Mon, 30 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712973-hdac3-inhibition-counteracts-autoimmune-demyelination-in-mice</link>
    </item>
    <item>
      <title>KYV-101 demonstrates CAR-mediated, CD19-dependent activity across neurological indications in vitro</title>
      <description>
        <![CDATA[Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of patients with B-cell-driven neurologic autoimmune diseases, including multiple sclerosis and myasthenia gravis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712967</guid>
      <pubDate>Mon, 30 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712967-kyv-101-demonstrates-car-mediated-cd19-dependent-activity-across-neurological-indications-in-vitro</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-spine-arm-nerves.webp?t=1716390498" type="image/jpeg" medium="image" fileSize="219668">
        <media:title type="plain">Nervous system illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Anti-IL-6 receptor inhibition attenuates myelitis severity </title>
      <description>
        <![CDATA[Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies. Satralizumab, a humanized anti-IL-6 receptor (IL-6R) antibody, has been approved for the treatment of NMOSD but the effects of IL-6R inhibition in myelitis severity have not been fully explored.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712874</guid>
      <pubDate>Fri, 27 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712874-anti-il-6-receptor-inhibition-attenuates-myelitis-severity</link>
    </item>
    <item>
      <title>CN-045 stimulates remyelination in multiple sclerosis models</title>
      <description>
        <![CDATA[The differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes (OLs) promotes the remyelination in human brain. In multiple sclerosis (MS), dysfunctional OPC differentiation leads to remyelination failure and subsequent severe neurological disability.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712824</guid>
      <pubDate>Thu, 26 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712824-cn-045-stimulates-remyelination-in-multiple-sclerosis-models</link>
    </item>
    <item>
      <title>PF-4778574 exerts neuroprotective effect in EAE models </title>
      <description>
        <![CDATA[High extracellular glutamate levels damage axons, myelin and oligodendrocytes in the context of inflammatory demyelinating disorders such as multiple sclerosis (MS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/712822</guid>
      <pubDate>Thu, 26 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712822-pf-4778574-exerts-neuroprotective-effect-in-eae-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Demyelination-of-a-neuron.webp?t=1687357719" type="image/jpeg" medium="image" fileSize="237601">
        <media:title type="plain">Demyelination of a neuron</media:title>
      </media:content>
    </item>
    <item>
      <title>ANK-700 protects from autoimmune disorder development </title>
      <description>
        <![CDATA[The assessment of glycosylated autoantigens as immunotolerance therapies is emerging as a potential strategy for the treatment of several autoimmune diseases, such as type 1 diabetes, Crohn’s disease or multiple sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712787</guid>
      <pubDate>Wed, 25 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712787-ank-700-protects-from-autoimmune-disorder-development</link>
    </item>
    <item>
      <title>ECTRIMS 2024: Driving a fast CAR on the MS road and beyond</title>
      <description>
        <![CDATA[Chimeric antigen receptor (CAR) T-cell therapy moved the needle at the 2024 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) congress and will continue to do so – not just in multiple sclerosis (MS), but in other autoimmune diseases as well.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712716</guid>
      <pubDate>Mon, 23 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712716-ectrims-2024-driving-a-fast-car-on-the-ms-road-and-beyond</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/CAR-T-cell-with-gene-strand.webp?t=1663195081" type="image/png" medium="image" fileSize="367541">
        <media:title type="plain">CAR T cell with implanted gene strand</media:title>
      </media:content>
    </item>
    <item>
      <title>Nanobody inhibiting complement in the brain protects mice from progressive MS</title>
      <description>
        <![CDATA[Investigators from Abzyme Therapeutics LLC have hypothesized that inhibiting this pathway in the CNS may prevent tissue damage and cease the progression of multiple sclerosis (MS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/712767</guid>
      <pubDate>Mon, 23 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712767-nanobody-inhibiting-complement-in-the-brain-protects-mice-from-progressive-ms</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Cross-section-of-brain.webp?t=1636061320" type="image/png" medium="image" fileSize="444252">
        <media:title type="plain">Cross section of brain</media:title>
      </media:content>
    </item>
    <item>
      <title>MS Aubagio tableau: Sanofi talks tolebrutinib, Immunic the pick? </title>
      <description>
        <![CDATA[The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s tolebrutinib, the central nervous system-penetrating Bruton's tyrosine kinase (BTK) inhibitor for multiple sclerosis (MS). Meanwhile, another player in the space, Immunic Inc., has caught the eye of Wall Street lately.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712670</guid>
      <pubDate>Fri, 20 Sep 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712670-ms-aubagio-tableau-sanofi-talks-tolebrutinib-immunic-the-pick</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Multiple-sclerosis-damaged-myelin.webp?t=1591729856" type="image/png" medium="image" fileSize="290740">
        <media:title type="plain">Multiple sclerosis-damaged myelin</media:title>
      </media:content>
    </item>
    <item>
      <title>Anti-CX3CR1 antibody prevents disease severity in multiple sclerosis model</title>
      <description>
        <![CDATA[Secondary progressive multiple sclerosis (SPMS) is a chronic form of disease that occurs after relapsing-remitting MS, with a progressive disease course, and its pathogenesis remains unclear. CX3C chemokine receptor 1 (CX3CR1) is a G protein-coupled receptor that may be a useful marker of Eomes+ Th cells; the antigen has been shown to be expressed by cytotoxic Th cells and required for late-onset disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712625</guid>
      <pubDate>Thu, 19 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712625-anti-cx3cr1-antibody-prevents-disease-severity-in-multiple-sclerosis-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies2.webp?t=1634753068" type="image/png" medium="image" fileSize="644719">
        <media:title type="plain">Antibodies illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>ECTRIMS 2024: Time for neuroprotection</title>
      <description>
        <![CDATA[The Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Copenhagen this week is celebrating its 40th edition. In recognition of this landmark, the plenary session and opening lecture were attended by Queen Margrethe of Denmark. Afterward, the hot topic session on neuroprotective therapies set the stage for the subsequent discussions on the latest trends in the management and treatment of multiple sclerosis (MS).]]>
      </description>
      <guid>http://www.bioworld.com/articles/712622</guid>
      <pubDate>Thu, 19 Sep 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712622-ectrims-2024-time-for-neuroprotection</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-neurological.webp?t=1745264568" type="image/jpeg" medium="image" fileSize="191694">
        <media:title type="plain">Brain waves</media:title>
      </media:content>
    </item>
    <item>
      <title>ECTRIMS opens: Biogen therapies did not reduce COVID-19 antibody responses in MS patients</title>
      <description>
        <![CDATA[Biogen Inc. opened the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) virtual meeting with data showing those treated with its multiple sclerosis (MS) therapies had an effective antibody response to COVID-19 vaccination.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512340</guid>
      <pubDate>Wed, 13 Oct 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512340-ectrims-opens-biogen-therapies-did-not-reduce-covid-19-antibody-responses-in-ms-patients</link>
    </item>
  </channel>
</rss>
